Showing results (11-20 of 33) with videos related to
Sort By:
Pageof 4
Antiviral Therapy|July 1, 1997
The role of didanosine in the management of HIV-1 infectionB G Gazzard, G J MoyleThe British Journal of Clinical Practice|May 1, 1995
Individualisation of HIV therapy: the clinician's perspectiveB G Gazzard, G J MoyleAntiviral Therapy|February 22, 2000
Finding a role for zalcitabine in the HAART eraG J Moyle, B G GazzardClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1993
Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virusM R Nelson, G J Moyle, B G GazzardHIV Medicine|February 24, 2006
Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophyG J Moyle, S Brown, L Lysakova, et al.The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|September 1, 1995
AIDS: clinical and scientific issues past, present and futureA G Dalgleish, G J Moyle, P Easterbrook, et al.Antiviral Therapy|August 1, 1996
Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study GroupG J Moyle, M Walker, R Harris, et al.The Quarterly Journal of Medicine|March 1, 1993
The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)G J Moyle, M R Nelson, D Hawkins, et al.Drugs|April 8, 1998
Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and useG J Moyle, B G Gazzard, D A Cooper, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|June 7, 2003
A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophyG J Moyle, C Baldwin, B Langroudi, et al.Pageof 4